Complications of tuberculosis
暂无分享,去创建一个
[1] Sandy F. Price,et al. Trends in Tuberculosis — United States, 2013 , 2014, MMWR. Morbidity and mortality weekly report.
[2] P. Draganov,et al. Hepatotoxic effects of therapies for tuberculosis , 2010, Nature Reviews Gastroenterology &Hepatology.
[3] D. Menzies,et al. Adverse reactions to first-line antituberculosis drugs , 2006, Expert opinion on drug safety.
[4] J. Chodakewitz,et al. Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir , 2009, Antimicrobial Agents and Chemotherapy.
[5] S. Lapinsky,et al. Mycobacterium tuberculosis septic shock. , 2013, Chest.
[6] H. Deshmukh,et al. Massive hemoptysis due to pulmonary tuberculosis: control with bronchial artery embolization. , 1996, Radiology.
[7] A. Denys,et al. Successful embolization of Rasmussen's aneurysm for severe haemoptysis. , 2004, Swiss medical weekly.
[8] A. Tunkel. Dexamethasone for treatment of tuberculous meningitis in adolescents and adults , 2005, Current infectious disease reports.
[9] H. Abeles,et al. The destroyed tuberculous lung. , 1974, Scandinavian journal of respiratory diseases.
[10] J. Kam,et al. Postpneumonectomy-like syndrome presenting in a patient with treated pulmonary tuberculosis: a case report , 2013, Journal of Medical Case Reports.
[11] Y. S. Kim,et al. Acute respiratory distress syndrome caused by miliary tuberculosis: a multicentre survey in South Korea. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[12] D. Schade,et al. A practical approach to hypercalcemia. , 2003, American family physician.
[13] Robert H. Pratt,et al. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] S. Lawn,et al. HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays , 2013, BMC Medicine.
[15] R. Ruimy,et al. Tuberculosis in the intensive care unit: a descriptive analysis in a low-burden country. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[16] Jing Wang,et al. Endobronchial tuberculosis: an overview , 2011, European Journal of Clinical Microbiology & Infectious Diseases.
[17] G. Schecter,et al. Linezolid in the treatment of multidrug-resistant tuberculosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] G. Meintjes,et al. Management of the Immune Reconstitution Inflammatory Syndrome , 2012, Current HIV/AIDS Reports.
[19] William R Bishai,et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial , 2009, The Lancet.
[20] K. Dooley,et al. Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine , 2013, Antimicrobial Agents and Chemotherapy.
[21] Lauren E. Manning,et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] R. Quinton,et al. Severe hypercalcaemia following vitamin D replacement for tuberculosis-associated hypovitaminosis D. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[23] K. Guntupalli,et al. Predictors of development and outcome in patients with acute respiratory distress syndrome due to tuberculosis. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[24] S. Vong,et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. , 2011, The New England journal of medicine.
[25] M. Iademarco. Availability of an Assay for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations for Its Use — United States, 2013 , 2013, MMWR. Morbidity and mortality weekly report.
[26] G. Churchyard,et al. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment , 2000, Thorax.
[27] U. Bauer,et al. [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.
[28] A. Pini,et al. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] T. Oppé,et al. Vitamin D deficiency. , 1979, British medical journal.
[30] Alimuddin Zumla,et al. Lung remodeling in pulmonary tuberculosis. , 2005, The Journal of infectious diseases.
[31] Lerato Mohapi,et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.
[32] Anneke Grobler,et al. Integration of antiretroviral therapy with tuberculosis treatment. , 2011, The New England journal of medicine.
[33] K. Dooley,et al. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. , 2009, The American journal of tropical medicine and hygiene.
[34] S. Bae,et al. Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis. , 2011, Journal of infection and public health.
[35] A. Diacon,et al. Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears , 2007, Antimicrobial Agents and Chemotherapy.
[36] Charles M Heilig,et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. , 2009, American journal of respiratory and critical care medicine.
[37] Simon Wandel,et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.
[38] Hojoong Kim,et al. Surgical correction of postpneumonectomy-like syndrome in a patient with a tuberculosis-destroyed lung. , 2008, The Journal of thoracic and cardiovascular surgery.
[39] S. Dorman,et al. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals , 2014, AIDS.
[40] T. Shim,et al. Pulmonary tuberculosis with acute respiratory failure , 2008, European Respiratory Journal.
[41] Z. Hasan,et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’ , 2013, BMC Infectious Diseases.
[42] Dao-xin Wang,et al. Predictors and outcome of patients with acute respiratory distress syndrome caused by miliary tuberculosis: a retrospective study in Chongqing, China , 2012, BMC Infectious Diseases.
[43] G. Maartens,et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome , 2010, AIDS.
[44] B. Mayosi,et al. Interventions for treating tuberculous pericarditis. , 2002, The Cochrane database of systematic reviews.
[45] E. Houpt,et al. Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA , 2010, Emerging infectious diseases.
[46] M. Sodemann,et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. , 2009, American journal of respiratory and critical care medicine.
[47] D. Follmann,et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.
[48] J. Baeten,et al. Mycobacterium tuberculosis Bacteremia in a Cohort of HIV-Infected Patients Hospitalized with Severe Sepsis in Uganda–High Frequency, Low Clinical Sand Derivation of a Clinical Prediction Score , 2013, PloS one.
[49] A. Bayer,et al. Pulmonary aspergilloma. Diagnostic and therapeutic considerations. , 1983, Archives of internal medicine.
[50] J. Farrar,et al. Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study , 2007, The Lancet Neurology.
[51] Charles L Daley,et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.
[52] Johan Schoeman,et al. Tuberculous meningitis: more questions, still too few answers , 2013, The Lancet Neurology.
[53] R. Smego,et al. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[54] Y. Ryu,et al. Clinical outcomes and prognostic factors in patients with tuberculous destroyed lung. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[55] R. Wilkinson,et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[56] T. Shim,et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis , 2012, European Respiratory Journal.
[57] Marcos Abdo Arbex,et al. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. , 2010, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.
[58] K. Dooley,et al. Tuberculosis and diabetes mellitus: convergence of two epidemics. , 2009, The Lancet. Infectious diseases.
[59] R. Chaisson,et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.
[60] E. Kantharaj,et al. Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.
[61] Marcos Abdo Arbex,et al. Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha , 2010 .
[62] Marcos Abdo Arbex,et al. Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha , 2010 .
[63] P. Willcox,et al. Chronic obstructive airways disease following treated pulmonary tuberculosis. , 1989, Respiratory medicine.
[64] S. Bilaçeroğlu,et al. Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[65] H. A. Thomas,et al. Embolization of multiple Rasmussen aneurysms as a treatment of hemoptysis. , 1994, Radiology.
[66] R. Chaisson,et al. Diagnostic Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in Hospitalized Patients in a High HIV Prevalence Setting , 2009, Journal of acquired immune deficiency syndromes.
[67] Aspergilloma and residual tuberculous cavities--the results of a resurvey. , 1970, Tubercle.
[68] R. Chaisson,et al. Quantitative Analysis of a Urine-Based Assay for Detection of Lipoarabinomannan in Patients with Tuberculosis , 2010, Journal of Clinical Microbiology.
[69] N. Santelmo,et al. Surgery for the sequelae of postprimary tuberculosis. , 2012, Thoracic surgery clinics.
[70] G. Borm,et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. , 2013, The Lancet. Infectious diseases.
[71] Keertan Dheda,et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies , 2013, BMC Infectious Diseases.
[72] C. Peloquin. Use of therapeutic drug monitoring in tuberculosis patients. , 2004, Chest.
[73] Christopher Dye,et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.
[74] J. Critchley,et al. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. , 2013, The Lancet. Infectious diseases.
[75] K. Dooley,et al. Pipeline of drugs for related diseases: tuberculosis , 2013, Current opinion in HIV and AIDS.
[76] N. Dendukuri,et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults , 2014, The Cochrane database of systematic reviews.
[77] S. Lawn,et al. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review , 2012, BMC Infectious Diseases.
[78] D. Mitchison,et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[79] L. Soto-Ramírez,et al. [Treatment of tuberculosis]. , 1997, Gaceta medica de Mexico.
[80] B. Mayosi,et al. A modern approach to tuberculous pericarditis. , 2007, Progress in cardiovascular diseases.